Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases

US9221826B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Stephen T. Wrobleski · Whitehouse Station, US
• Jagabandhu Das · Mercerville, US
• Lidia M. Doweyko · Vero Beach, US
• Junqing Guo · Princeton, US
• John Hynes · Washington Crossing, US
• Bin Jiang · Norristown, US
• James Kempson · Princeton, US
• Shuqun Lin · Newtown, US
• Steven H. Spergel · Warrington, US
• John S. Tokarski · Princeton, US
• Hong Wu · Meekrap-oord, CN
• Bingwei Yang · Montgomery, US

Key dates

• Filing date: Mar 16, 2012
• Grant date: Dec 29, 2015
• Expiry date: Mar 16, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.